Upregulation of GPR109A in Parkinson's disease

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Wakade, Chandramohan ^a   Chong, Raymond ^a   Bradley, Eric ^a   Thomas, Bobby ^b   Morgan, John ^b  

^a AUGUSTA UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; CYTOKINE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 7; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINIC ACID; PROTEIN GPR109A; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; UNCLASSIFIED DRUG; HCAR2 PROTEIN, HUMAN; NICOTINIC RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NIGHT SLEEP; PAIN ASSESSMENT; PARKINSON DISEASE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUESTIONNAIRE; REM SLEEP; SLEEP DEPRIVATION; SLEEP DISORDER; SLEEP QUALITY; STAINING; SUBSTANTIA NIGRA; UPREGULATION; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SLEEP;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NIACIN; PARKINSON DISEASE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; SLEEP; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 84908128112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109818     Document Type: Article

References (69)

1. Barnum CJ, Tansey MG (2010) Modeling neuroinflammatory pathogenesis of Parkinson's disease. Progress in Brain Research 184: 113-132.
2. Banati RB, Daniel SE, Blunt SB (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Movement Disorders 13: 221-227.
3. Crotty S, Fitzgerald P, Tuohy E, Harris DM, Fisher A, et al. (2008) Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease. European Journal of Neuroscience 27: 294-300.
4. Gagne JJ, Powers MC (2010) Anti-inflammatory drugs and risk of Parkinson's disease: A meta-analysis Neurology 74: 995-1002.
5. Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, et al. (2006) Langerhans cells release prostaglandin D2 in response to nicotinic acid. Journal of Investigative Dermatology 126: 2637-2646.
6. Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, et al. (2010) Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, rantes, and mcp-1 and upregulation of adiponectin. Atherosclerosis 209: 89-95.
7. Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai J, et al. (2012) Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arteriosclerosis, Thrombosis, and Vascular Biology 32: 669-676.
8. Digby JE, Martinez FO, Jefferson A, Ruparelia N, Wamil M, et al. (2011) Anti-inflammatory effects of nicotnic acid: Mechanisms of action in human monocytes. Circulation Supplement 124: A14830.
9. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML (2009) Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202: 68-75.
10. Offermanns S (2006) The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends in Pharmacological Sciences 27: 384-390.
11. Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, et al. (2005) (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. Journal of Biological Chemistry 280: 26649-26652.
12. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, et al. (2009) Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. Journal of Neuroscience 29: 13435-13444.
13. Lawrence T, Natoli G (2011) Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nature Reviews Immunology 11: 750-761.
14. Hasan D, Chalouhi N, Jabbour P, Hashimoto T (2012) Macrophage imbalance (M1 vs. M2) and upregulation of mast cells in wall of ruptured human cerebral aneurysms: preliminary results. Journal of Neuroinflammation 9: 222.
15. Peek CB, Affinati AH, Ramsey KM, Kuo HY, Yu W, et al. (2013) Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science 342: 1243417.
16. Imai S (2010) "Clocks" in the NAD World: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochimica et Biophysica Acta 1804: 1584-1590.
17. Reimund E (1991) Sleep deprivation-induced neuronal damage may be due to nicotinic acid depletion. Medical Hypotheses 34: 275-277.
18. Sancar G, Brunner M (2014) Circadian clocks and energy metabolism. Cellular and Molecular Life Sciences.
19. Yoshino J (2013) [Importance of NAMPT-mediated NAD-biosynthesis and NAD-dependent deacetylase SIRT1 in the crosstalk between circadian rhythm and metabolism]. Nihon Rinsho Japanese Journal of Clinical Medicine 71: 2187-2193.
20. Martin PM, Ananth S, Cresci G, Roon P, Smith S, et al. (2009) Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. Molecular Vision 15: 362-372.
21. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, et al. (2000) D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 97: 5440-5444.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry 55: 181-184.
23. Wakade C, Sukumari-Ramesh S, Laird MD, Dhandapani KM, Vender JR (2010) Delayed reduction in hippocampal postsynaptic density protein-95 expression temporally correlates with cognitive dysfunction following controlled cortical impact in mice. Journal of Neurosurgery 113: 1195-1201.
24. Shambroom JR, Fabregas SE, Johnstone J (2011) Validation of an automated wireless system to monitor sleep in healthy adults. Journal of Sleep Research.
25. Cohen J (1988) Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates.
26. Stebbins GT, Goetz CG, Lang AE, Cubo E (1999) Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. Movement Disorders 14: 585-589.
27. Han M, Nagele E, DeMarshall C, Acharya N, Nagele R (2012) Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PloS One 7: e32383.
28. Wakade C, Chong RK, Bradley E, Morgan J (2014) Niacin supplementation modulates GPR109A levels and NAD-NADH ratio and ameliorates PD symptoms. Submitted.
29. Piper PW, Harris NL, MacLean M (2006) Preadaptation to efficient respiratory maintenance is essential both for maximal longevity and the retention of replicative potential in chronologically ageing yeast. Mechanisms of Ageing and Development 127: 733-740.
30. Belenky P, Racette FG, Bogan KL, McClure JM, Smith JS, et al. (2007) Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 129: 473-484.
31. Jia H, Li X, Gao H, Feng Z, Zhao L, et al. (2008) High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease. Journal of Neuroscience Research 86: 2083-2090.
32. Arduino DM, Esteves AR, Oliveira CR, Cardoso SM (2010) Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson's disease. CNS & Neurological Disorders Drug Targets 9: 105-119.
33. Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, et al. (2014) Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Molecular Medicine 6: 721-731.
34. Sasaki Y, Araki T, Milbrandt J (2006) Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. Journal of Neuroscience 26: 8484-8491.
35. Ban N, Ozawa Y, Inaba T, Miyake S, Watanabe M, et al. (2013) Light-dark condition regulates sirtuin mRNA levels in the retina. Experimental Gerontology 48: 1212-1217.
36. Chang HC, Guarente L (2013) SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 153: 1448-1460.
37. Jung-Hynes B, Reiter RJ, Ahmad N (2010) Sirtuins, melatonin and circadian rhythms: Building a bridge between aging and cancer. Journal of Pineal Research 48: 9-19.
38. Boeve BF (2013) Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurology 12: 469-482.
39. Chahine LM, Daley J, Horn S, Colcher A, Hurtig H, et al. (2013) Questionnaire-based diagnosis of REM sleep behavior disorder in Parkinson's disease. Movement Disorders 28: 1146-1149.
40. Poewe W (2006) The natural history of Parkinson's disease. Journal of Neurology 253 Suppl 7: VII2-6.
41. Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY (2012) How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 135: 1860-1870.
42. Peeraully T, Yong MH, Chokroverty S, Tan EK (2012) Sleep and Parkinson's disease: a review of case-control polysomnography studies. Movement Disorders 27: 1729-1737.
43. Sixel-Doring F, Trautmann E, Mollenhauer B, Trenkwalder C (2011) Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology 77: 1048-1054.
44. Ramsey KM, Affinati AH, Peek CB, Marcheva B, Hong HK, et al. (2013) Circadian measurements of sirtuin biology. Methods in Molecular Biology 1077: 285-302.
45. Mendelsohn AR, Larrick JW (2014) Partial reversal of skeletal muscle aging by restoration of normal NAD(+) Levels. Rejuvenation Research 17: 62-69.
46. Asher G, Schibler U (2011) Crosstalk between components of circadian and metabolic cycles in mammals. Cell Metabolism 13: 125-137.
47. Bellet MM, Sassone-Corsi P (2010) Mammalian circadian clock and metabolism - the epigenetic link. Journal of Cell Science 123: 3837-3848.
48. Ghosh S, George S, Roy U, Ramachandran D, Kolthur-Seetharam U (2010) NAD: A master regulator of transcription. Biochimica et Biophysica Acta 1799: 681-693.
49. Sassone-Corsi P (2012) Minireview: NAD(+), a circadian metabolite with an epigenetic twist. Endocrinology 153: 1-5.
50. Gille A, Bodor ET, Ahmed K, Offermanns S (2008) Nicotinic acid: Pharmacological effects and mechanisms of action. Annual Review of Pharmacology and Toxicology 48: 79-106.
51. Alisky JM (2005) Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash-a case report. Nutritional Neuroscience 8: 327-329.
52. Fall PA, Fredrikson M, Axelson O, Granerus AK (1999) Nutritional and occupational factors influencing the risk of Parkinson's disease: A case-control study in southeastern Sweden. Movement Disorders 14: 28-37.
53. Bender DA, Earl CJ, Lees AJ (1979) Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clinical Science 56: 89-93.
54. Hoane MR, Tan AA, Pierce JL, Anderson GD, Smith DC (2006) Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat. Journal of Neurotrauma 23: 1535-1548.
55. Anderson DW, Bradbury KA, Schneider JS (2008) Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. European Journal of Neuroscience 28: 610-617.
56. Chen J, Cui X, Zacharek A, Jiang H, Roberts C, et al. (2007) Niaspan increases angiogenesis and improves functional recovery after stroke. Annals of Neurology 62: 49-58.
57. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, et al. (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47: 397-403.
58. Chai JT, Digby JE, Choudhury RP (2013) GPR109A and vascular inflammation. Current Atherosclerosis Reports 15: 325.
59. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, et al. (2011) Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World Journal of Gastroenterology 17: 1519-1528.
60. Birkmayer JG, Vrecko C, Volc D, Birkmayer W (1993) Nicotinamide adenine dinucleotide (NADH)-a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta neurologica Scandinavica Supplementum 146: 32-35.
61. Pearl SM, Antion MD, Stanwood GD, Jaumotte JD, Kapatos G, et al. (2000) Effects of NADH on dopamine release in rat striatum. Synapse 36: 95-101.
62. (2003) The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations. Movement Disorders 18: 738-750.
63. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, et al. (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. Movement Disorders 19: 1020-1028.
64. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12: 189-198.
65. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age Ageing 26: 353-357.
66. Jenkinson C, Fitzpatrick R (2007) Cross-cultural evaluation of the short form 8-item Parkinson's Disease Questionnaire (PDQ-8): Results from America, Canada, Japan, Italy and Spain. Parkinsonism and Related Disorders 13: 22-28.
67. Chong RK, Morgan J, Mehta SH, Pawlikowska I, Hall P, et al. (2011) Rapid assessment of postural instability in Parkinson's disease (RAPID): A pilot study. European Journal of Neurology 18: 260-265.
68. Chong RK, Lee KH, Morgan J, Mehta SH, Hall P, et al. (2012) Diagnostic value of the rapid assessment of postural instability in Parkinson's disease (RAPID) questionnaire. International Journal of Clinical Practice 66: 718-721.
69. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, et al. (2002) The Parkinson's disease sleep scale: A new instrument for assessing sleep and nocturnal disability in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 73: 629-635.